GMP deadline for pharma firms likely to be extended

WITH NEARLY 75% of pharmaceutical units yet to begin the upgrading work for their manufacturing facilities, the government might be forced to extend the deadline to implement revised Schedule M guidelines for smalland medium-sized pharma units beyond the year-end, sources close to the development told FE.

- MANU KAUSHIK

Even for the 1,700-odd units that had applied for extension with the Central Drugs Standard Control Organisation (CDSCO) this year, 20-30% of the upgradation work is still pending.